Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — FY2026 Earnings Presentation
30 slides from Prestige Consumer Healthcare's earnings presentation, May 14, 2026
Slide 1: Full-Year Fiscal 2026 Results
Full-Year Fiscal 2026 Results May 14th, 2026
Slide 2: Safe Harbor Disclosure
Safe Harbor Disclosure This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenues, organic revenue growth, adjusted diluted E
Slide 3: Agenda for Today's Discussion
Agenda for Today’s Discussion I. FY 26 and Performance Recap II. Drivers of Portfolio Growth III. Financial Overview IV.FY 27 Outlook & The Road Ahead FULL-YEAR FY 26 RESULTS 3
Slide 4: I. FY 26 and Performance Recap
I. FY 26 and Performance Recap FULL-YEAR FY 26 RESULTS
Slide 5: FY 26 Performance Recap
FY 26 Performance Recap ◼ Revenue of $1.089 billion, down 4.3% versus prior year FY 26 Sales ◼ Eye care sales impacted by production volatility and capacity & quality upgrades Highlights ◼ International segment impacted by eye care supply and distributor order patterns ◼ Adjusted Gross Margin(2) of
Slide 6: History of Superior Performance
History of Superior Performance Proven Ability to Execute Value Creation Strategy 1 Investing for Growth with Proven Brand-Building Playbook 2 Superior Business Attributes Enable Free Cash Flow 3 Scalable & Efficient Platform Supports Disciplined Capital Allocation +2.9% +6.2% +2.9% 5-Yr CAGR 5-Yr C
Slide 7: Eye Care Outlook One Quarter Into Pillar5 Ownership
Eye Care Outlook One Quarter Into Pillar5 Ownership Progress Made in 2026 FY 2027 Outlook ◼ Continued capex prioritization to enhance supply ◼ Eye Care supply ramp remains a strategic priority quality and resilience ◼ Meaningful progress on integration of Pillar5 after first ◼ Anticipate sales impro
Slide 8: II. Drivers of Portfolio Growth
II. Drivers of Portfolio Growth FULL-YEAR FY 26 RESULTS
Slide 9: Proven Brand-Building Tactics Continue to Drive GI Growth
Proven Brand-Building Tactics Continue to Drive GI Growth Brand-Building Driving Expanding Category Reach in Multiple Ways Consumption Sustained Share Gains Growth Defend Motion Sickness Leadership with Engaging Content Market Share & YoY $ Sales Growth* #2 Brand (5%) ~57% Accelerate Penetration in
Slide 10: Innovation Playbook Wide-Ranging to Address Consumer Needs
Innovation Playbook Wide-Ranging to Address Consumer Needs Product Development Initiatives Extend Brand Through Better Consumer Experience or Claims Innovate Through Technology or Forms GLP-1 GLP-1 Mental New Categories Expansion Skin Tags friendly friendly Alertness FULL-YEAR FY 26 RESULTS 10
Slide 11: Continue to Drive Strong E-Commerce Growth
Continue to Drive Strong E-Commerce Growth E-Commerce as a % of Net Sales* Optimizing Content to Changing Consumer Behavior with AI Adoption ~18% New Product Development Seasonal Content Brand Refresh ~16% ~14% +4.5x ~11% ~4% FY 19 FY 21 FY 23 FY 25 FY 26 Continued strong performance across E-Commer
Slide 12: III. Financial Overview
III. Financial Overview FULL-YEAR FY 26 RESULTS
Slide 13: Fourth Quarter and FY Performance
Fourth Quarter and FY 26 Performance FY 26 FY 25 (5.0%) Revenue of $281.6 million, down 6.4% vs. prior year on an organic basis(1) $281.6 $296.5 (7.7%) Q4 $96.4 $104.4 (6.8%) $1.23 $1.32 (2) (2) Revenue Adjusted EBITDA Adjusted EPS Adjusted EBITDA(2) of $96.4 million compared to $104.4 million prior
Slide 14: Detailed Financial Results for FY 26
Detailed Financial Results for FY 26 3 Months Ended 12 Months Ended FY 26 Comments Q4 FY 26 Q4 FY 25 % Chg FY 26 FY 25 % Chg ◼ Revenue down 4.5% organically(1) versus prior Total Revenue $ 281.6 $ 296.5 (5.0%) $ 1,088.7 $ 1,137.8 (4.3%) year Adj. Gross Profit(2) 155.9 170.0 (8.3%) 605.2 634.5 (4.6%)
Slide 15: Strong Free Cash Flow Continued in FY 26
Strong Free Cash Flow Continued in FY 26 Free Cash Flow(2) & Net Leverage(3) Key Attributes Enabling Efficient Allocation Model with Low Capital Expenditures Repurchased $156 million $243 $246 (2.3 million shares) in FY 26 $239 Leading $222 Margin Profile Investing in eye care manufacturing capabili
Slide 16: Disciplined Capital Allocation Priorities
Disciplined Capital Allocation Priorities 1 Invest in Current Brands to Drive Organic Growth 2 Focused on Debt Reduction to Enhance Optionality Prioritize Deleveraging Following Acquisition of Breathe Right® Anticipate approximately $900 million total Free Cash Flow(4) 3 Strategic Share Repurchases
Slide 17: IV. FY 27 Outlook & The Road Ahead
IV. FY 27 Outlook & The Road Ahead FULL-YEAR FY 26 RESULTS
Slide 18: Portfolio & Strategy Well-Positioned for Continued Value Creation
Portfolio & Strategy Well-Positioned for Continued Value Creation 1 Diversified Portfolio of Leading, Trusted Brands 2 Established Organic Growth Playbook 3 Superior Financial Profile Generating Consistent Cash Flow 4 Scalable Platform 5 Organic Growth Engine Reinforced by M&A Prestige’s Business At
Slide 19: Initial FY 27 Outlook
Initial FY 27 Outlook ◼ Revenues of $1,100 to $1,121 million — Organic growth of approximately 1% to 3% Top Line Trends ◼ Continue to emphasize brand-building across a diverse, needs-based portfolio ◼ Projecting improved shipment trends in eye care ◼ Pending acquisitions not yet included ◼ Adjusted
Slide 20: M&A Strategy at Work: Portfolio-Enhancing Consumer Health Deals
M&A Strategy at Work: Portfolio-Enhancing Consumer Health Deals Breathe Right® & Other OTC Brands LaCorium Health ~10% ~34% ~20% Other ~$200M ~$40M Loyalty Brands Revenue Revenue ~66% ~70% #1 Category- Leader in therapeutic Synonymous Brand lip, skin, and foot care with Global Reach ✓ Iconic #1 bran
Slide 21: Three-Year Roadmap Points to Outsized Value Creation
Three-Year Roadmap Points to Outsized Value Creation Revenue Growth Financial Discipline Leading Free Cash Flow ✓ Accretive revenue growth from ✓ Disciplined financial management ✓ Proven strong & sustainable free Breathe Right & LaCorium to sustain earnings momentum cash flow model ✓ Fast-growing I
Slide 22: Q&A
Q&A Prestige Consumer HEALTHCARE
Slide 23: Appendix
Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measure in the attached Reconciliation Schedules and / or our earnings release dated May 13, 2026 in the “About Non-GAAP Financial Measures” section. (2) Adjusted Gross Profit, A
Slide 24: Reconciliation Schedules
Reconciliation Schedules Organic Revenue Change Three Months Ended March 31, Year Ended March 31, 2026 2025 2026 2025 (In Thousands) GAAP Total Revenues $ 281,617 $ 296,518 $ 1,088,705 $ 1,137,762 Revenue Change (5.0%) (4.3%) Adjustments: Impact of foreign currency exchange rates - 4,292 - 2,718 Tot
Slide 25: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted G&A Expense Three Months Ended March 31, Year Ended March 31, 2026 2025 2026 2025 (In Thousands) GAAP General and Administrative Expense $ 30,280 $ 27,050 $ 116,447 $ 108,209 GAAP General and Administrative Expense as a Percentage of GAAP Total Revenue 1
Slide 26: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted EBITDA and EBITDA Margin Three Months Ended March 31, Year Ended March 31, 2026 2025 2026 2025 (In Thousands) GAAP Net Income $ 53,928 $ 50,128 $ 190,301 $ 214,605 Interest expense, net 11,428 10,759 42,339 47,632 Provision for income taxes 10,844 23,831
Slide 27: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted Net Income & Adjusted Diluted EPS Three Months Ended March 31, Year Ended March 31, 2026 2025 2026 2025 2021 Net Adjusted Net Adjusted Net Adjusted Net Adjusted Net Adjusted Income EPS Income EPS Income EPS Income EPS Income EPS (In Thousands, except per
Slide 28: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted Free Cash Flow Three Months Ended March 31, Year Ended March 31, 2026 2025 2026 2025 (In Thousands) GAAP Net Income $ 53,928 $ 50,128 $ 190,301 $ 214,605 Adjustments: Adjustments to reconcile net income to net cash provided by operating activities as sho
Slide 29: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Projected Adjusted Earnings Per Share Low High Projected FY'27 GAAP Diluted EPS $ 4.31 $ 4.40 Costs associated with Pillar5 manufacturing optimization and integration $ 0.11 $ 0.11 Projected FY'27 Non-GAAP Adjusted Diluted EPS $ 4.42 $ 4.51 Projected Free Cash Fl
Slide 30: FY 27 Financial Outlook
FY 27 Financial Outlook Metric Guidance ◼ $1.100 to $1.121 billion Revenue ◼ Organic growth of 1% to 3%(1) Gross Margin ◼ 55.0 to 56.0% Marketing ◼ Over 13% of net revenue General & Administrative ◼ ~10.5% of net revenue Interest Expense ◼ $43 million in interest expense Tax Rate ◼ ~24% effective ta
Prestige Consumer Healthcare — FY2026 Earnings Presentation on 6ix